{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:29:05Z","timestamp":1791854945310,"version":"4.3.4"},"reference-count":58,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Internet Res"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 (GLP-1) medications, recently introduced in the United States for treating type 2 diabetes and obesity, have sparked interest and discussion on social media. Social media has emerged as a prominent platform for the distribution of health information; its vast user base and accessibility make it a popular resource for individuals seeking medical advice. This study characterized GLP-1 medication\u2013related content on Instagram about 3 critical areas of public health: women\u2019s health, access from nontraditional settings, and barriers to access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to perform passive content analysis in which information patterns would be observed from Instagram posts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined 40 GLP-1 medication\u2013related Instagram posts to develop a list of the most frequently used hashtags. In total, 10 \u201ctop posts\u201d were collected for 7 days (July 11-17, 2023) for 11 study hashtags (eg, #Ozempic). Duplicates, deleted posts or accounts, non-English content, and unrelated posts were removed. Each post was reviewed by at least 2 coders. Coding discrepancies were resolved through discussion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final sample included 239 posts. More than half of the posts (130\/239, 54%) were from GLP-1 medication users. Raters perceived most users to be female (90\/97, 92.8%); inferred that most used medications for weight loss (69\/130, 53.1%); determined the most frequently noted health condition was polycystic ovarian syndrome (25\/130, 19.2%); and judged posts to have positive sentiments about well-being (64\/130, 49.2%) and toward the medications (100\/130, 76.9%). About a quarter of the posts (55\/239, 23%) offered services for obtaining GLP-1 medications; GLP-1 medications were perceived to be accessible via nontraditional health care settings (eg, medical spas) versus traditional settings (39\/239,16.3% vs 12\/239, 5%). Most users (78\/97, 80.4%) were perceived to be White; barriers to access (ie, shortages, insurance, and cost) were infrequently mentioned (6\/239, 2.5%; 3\/239, 1.3%; and 1\/239, 0.4%, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight the perceived benefits of GLP-1 medications for women\u2019s health, the need to increase health literacy about where to safely access medications, and how additional attention is needed for equitable access to GLP-1 medications. The onus is on social media companies to promote content that is safe and for the health care system and its payers to address health care inequities for historically marginalized communities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/66400","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T10:45:07Z","timestamp":1754822707000},"page":"e66400","source":"Crossref","is-referenced-by-count":4,"title":["How Glucagon-Like Peptide-1 Medications Are Depicted in Instagram Posts Regarding Women\u2019s Health, Nontraditional Access, and Barriers to Access: Content Analysis"],"prefix":"10.2196","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-2359","authenticated-orcid":false,"given":"Brittnie E","family":"Bloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-7173","authenticated-orcid":false,"given":"Marie A","family":"Bragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-3120","authenticated-orcid":false,"given":"Melanie R","family":"Jay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-5989","authenticated-orcid":false,"given":"Daphna","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3795-9104","authenticated-orcid":false,"given":"Camile","family":"Cline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1662-2527","authenticated-orcid":false,"given":"Matthew","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2165-7320","authenticated-orcid":false,"given":"Avery","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4866-679X","authenticated-orcid":false,"given":"Sandhya","family":"Muthuramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7270-9915","authenticated-orcid":false,"given":"Roberto","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-3742","authenticated-orcid":false,"given":"Stephanie L","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1108\/lht-02-2020-0024"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.1933"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2023.116387"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2023.100013"},{"key":"ref5","first-page":"22","author":"Shalabi, M","year":"2025","journal-title":"Afr J Diabetes Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2196\/24336"},{"key":"ref7","unstructured":"Lovelace JrBBeyond Ozempic: new GLP-1 drugs promise weight loss and health benefitsNBC News2025-06-06https:\/\/www.nbcnews.com\/health\/health-news\/beyond-ozempic-glp-1-drugs-promise-weight-loss-health-benefits-rcna157525"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01992-4"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001588"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-001952"},{"key":"ref11","unstructured":"PeetzCWeight-loss drugs are the talk of social media, and teens are listeningEducation Week2025-06-26https:\/\/www.edweek.org\/leadership\/weight-loss-drugs-are-the-talk-of-social-media-and-teens-are-listening\/2024\/03"},{"key":"ref12","unstructured":"O'NeillLOzempic, body positivity, and influencers: the complex world of weight loss drugsThe Washington Post2025-06-06https:\/\/www.washingtonpost.com\/style\/of-interest\/2024\/02\/14\/ozempic-body-positivity-influencers-weight-loss-drugs\/"},{"key":"ref13","unstructured":"RapaportLTirzepatide (Mounjaro) helped people lose over 60 pounds in new studyEveryday Health2025-06-06https:\/\/www.everydayhealth.com\/obesity\/tirzepatide-mounjaro-helped-people-lose-over-sixty-pounds-in-new-study\/"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2196\/23205"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjad211"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1448"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13507"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4182"},{"key":"ref19","unstructured":"CollinsSTrending GLP-1 weight loss drugs are shipping to more American homesCNBC2025-06-06https:\/\/www.cnbc.com\/2023\/01\/20\/trending-glp-1-weight-loss-drugs-are-shipping-to-more-american-homes.html"},{"key":"ref20","unstructured":"KarlissARich people are hogging Ozempic, making the drug harder to access for people with diabetesSalon2025-06-06https:\/\/www.salon.com\/2023\/03\/06\/rich-people-are-hogging-ozempic-making-the-harder-to-access-for-people-with-diabetes\/"},{"key":"ref21","unstructured":"ReedMOzempic and other weight loss drugs: medicaid coverage issuesAxios2025-06-06https:\/\/www.axios.com\/2024\/02\/16\/ozempic-weight-loss-drugs-medicaid-coverage-glp-1"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185915"},{"key":"ref23","unstructured":"MullerJOzempic \u2018Oops\u2019 babies spark debate about weight-loss shot use as fertility drugsBloomberg2025-06-06https:\/\/www.bloomberg.com\/news\/articles\/2024-04-18\/ozempic-babies-doctors-want-safety-data-on-obesity-shots-during-pregnancy"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/S13063-022-07004-2"},{"key":"ref25","unstructured":"Code of Federal RegulationsU.S. Department of Health and Human Services20250825https:\/\/www.ecfr.gov\/current\/title-45\/part-46\/section-46.104#p-46.104(d)(4)(i)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109147"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bodyim.2020.05.001"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2196\/13544"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2021.05.038"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s41666-021-00102-x"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/08870446.2020.1792903"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.midw.2023.103623"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/17455057221125088"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2963"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(23)00033-0"},{"issue":"1","key":"ref36","first-page":"19","volume":"6","author":"Maqbool, M","year":"2022","journal-title":"Int J Curr Res Physiol Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpag.2023.10.007"},{"key":"ref38","unstructured":"RoySYoung people are increasingly using Wegovy and OzempicMichigan Medicine Health Lab2025-05-15https:\/\/www.michiganmedicine.org\/health-lab\/young-people-are-increasingly-using-wegovy-and-ozempic"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1525\/collabra.132410"},{"key":"ref40","unstructured":"TaubesGOzempic, Mounjaro, and the long-term effects of GLP-1 drugsThe Atlantic2025-05-15https:\/\/www.theatlantic.com\/health\/archive\/2024\/04\/ozempic-mounjaro-glp-1-long-term-effects\/678057\/"},{"key":"ref41","unstructured":"CourtEWegovy maker sues US pharmacy to block knock-offBloomberg2025-05-15https:\/\/www.bloomberg.com\/news\/articles\/2023-07-06\/novo-nordisk-sues-to-block-pharmacy-made-wegovy-knock-offs"},{"key":"ref42","unstructured":"CastronuovoCTikTokers put consumers at risk as drug ads go unchecked by FDABloomberg Law2025-05-15https:\/\/news.bloomberglaw.com\/health-law-and-business\/tiktokers-put-consumers-at-risk-as-drug-ads-go-unchecked-by-fda"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2499670"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5015"},{"key":"ref45","unstructured":"MullerJTikTok Ozempic influencers say new rules unfairly target themBloomberg2025-05-15https:\/\/www.bloomberg.com\/news\/articles\/2024-04-22\/tiktok-ozempic-influencers-say-new-rules-unfairly-target-them"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2025.100183"},{"key":"ref47","unstructured":"U.S.FAFDA approves first treatment to reduce the risk of serious heart problems specifically for adults with obesity or overweightU.S. Food and Drug Administration2025-05-15https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13111503"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020739"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2337\/cd23-0023"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9081005"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4182"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02669-x"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302323"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1108\/idd-03-2020-0033"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-015-0251-9"},{"key":"ref58","unstructured":"BackmanIPrices of expensive diabetes medicines and weight-loss drugs are drastically higher than production costsYale School of Medicine2025-05-13https:\/\/medicine.yale.edu\/news-article\/prices-of-expensive-diabetes-medicines-and-weight-loss-drugs-are-drastically-higher-than-production-costs\/"}],"container-title":["Journal of Medical Internet Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jmir.org\/2025\/1\/e66400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:59:24Z","timestamp":1785851964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmir.org\/2025\/1\/e66400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":58,"URL":"https:\/\/doi.org\/10.2196\/66400","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.66400","asserted-by":"object"}]},"ISSN":["1438-8871"],"issn-type":[{"value":"1438-8871","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}